Scientists at Fox Chase Cancer Center have identified a mutation in a common oncogene - a gene that can cause cancer - that ...

Verastem shows strong late-stage pipeline progress, financial discipline, and a diverse portfolio that support long-term ...

Researchers have identified a mutation in a common oncogene that may play an important role in colon cancer. Their findings ...

One mutation, called KRAS G12V, stood out from the others. All three mutations are involved in creating a molecule called acetyl-CoA, an important building block for fatty acids and proteins.

Blood-based circulating tumor DNA (ctDNA) testing has proven to be insufficient for detecting KRAS mutations in patients with ...

An RNA interference (RNAi) molecule that selectively targets the KRAS G12V mutation could represent a key advance in the ...

The KRAS G12C-[mutation] happens to be one of the rare KRAS mutations, occurring in 4% of patients. But this particular mutation is more druggable, [and] more amenable to inhibition. And it was one of ...

The research, published August 29 in Cancer Cell, demonstrates that KRAS mutations, which occur in about 95 percent of people who have PDAC, can vary, with KRAS-G12R, KRAS-G12D and KRAS-G12V being ...

The Food and Drug Administration (FDA) has granted accelerated approval to Avmapki ™ (avutometinib) plus Fakzynja ™ (defactinib) for the treatment of adult patients with KRAS- ...

In June 2025, AstraZeneca announced a Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy versus platinum-based SoC chemotherapy in the first-line ...

The research, published August 29 in Cancer Cell, demonstrates that KRAS mutations, which occur in about 95% of people who have PDAC, can vary, with KRAS-G12R, KRAS-G12D and KRAS-G12V being the ...